可药性
抗菌剂
药物发现
抗药性
生物
人类病原体
抗生素耐药性
药物开发
药品
计算生物学
微生物学
抗生素
药理学
细菌
生物信息学
生物化学
遗传学
基因
作者
Zachary W. Scott,Seoung‐ryoung Choi,Bradley E. Britigan,Prabagaran Narayanasamy
出处
期刊:ACS Infectious Diseases
[American Chemical Society]
日期:2023-03-30
卷期号:9 (4): 716-738
被引量:4
标识
DOI:10.1021/acsinfecdis.3c00050
摘要
The treatment of infections is becoming more difficult due to emerging resistance of pathogens to existing drugs. As such, alternative druggable targets, particularly those that are essential for microbe viability and thus make it harder to develop resistance, are desperately needed. In turn, once identified, safe and effective agents that disrupt these targets must be developed. Microbial acquisition and use of iron is a promising novel target for antimicrobial drug development. In this Review we look at the various facets of iron metabolism critical to human infection with pathogenic microbes and the various ways in which it can be targeted, altered, disrupted, and taken advantage of to halt or eliminate microbial infections. Although a variety of agents will be touched upon, the primary focus will be on the potential use of one or more gallium complexes as a new class of antimicrobial agents. In vitro and in vivo data on the activity of gallium complexes against a variety of pathogens including ESKAPE pathogens, mycobacteria, emerging viruses, and fungi will be discussed in detail, as well as pharmacokinetics, novel formulations and delivery approaches, and early human clinical results.
科研通智能强力驱动
Strongly Powered by AbleSci AI